|
⚲
|
| Keyboard |
| Abernethy Matt
✚
|
|
|---|---|
| CIK # | 0001724097 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001724097] | |
| 4 | [0001724097] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Fate Therapeutics Inc | |
| Abernethy Matt | |
| Neurocrine Biosciences Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-03-04 | Gift | 2,249 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-13 | Tax withheld | 5,378 | $124.12 | 667,517 |
|
Neurocrine Biosciences Inc NBIX
Stock Option · derivative
|
2026-02-13 | Grant | 44,095 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Restricted Stock Unit · derivative
|
2026-02-13 | Option exercise | 2,241 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-13 | Tax withheld | 1,385 | $124.12 | 171,906 |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-13 | Tax withheld | 1,210 | $124.12 | 150,185 |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-13 | Option exercise | 2,566 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-13 | Grant | 9,968 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Restricted Stock Unit · derivative
|
2026-02-13 | Option exercise | 2,566 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Restricted Stock Unit · derivative
|
2026-02-13 | Grant | 7,735 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-13 | Option exercise | 2,241 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Restricted Stock Unit · derivative
|
2026-02-12 | Option exercise | 2,133 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-12 | Option exercise | 2,133 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-02-12 | Tax withheld | 1,151 | $123.10 | 141,688 |
|
Neurocrine Biosciences Inc NBIX
Restricted Stock Unit · derivative
|
2026-01-31 | Option exercise | 2,437 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-01-31 | Option exercise | 2,437 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2026-01-31 | Tax withheld | 1,368 | $136.06 | 186,130 |
|
Fate Therapeutics Inc FATE
Stock Option (Right to Buy) · derivative
|
2025-05-29 | Grant | 110,000 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Restricted Stock Unit · derivative
|
2025-02-13 | Option exercise | 2,241 | $0.00 | |
|
Neurocrine Biosciences Inc NBIX
Common Stock
|
2025-02-13 | Option exercise | 2,566 | $0.00 | |
| showing 20 of 88 most recent transactions | |||||